FDA.reportPublic FDA data

Tivicay PD 5 MG Tablet for Oral Suspension

RxCUI
2374566
RxNorm name
Tivicay PD 5 MG Tablet for Oral Suspension
Display name
Tivicay PD 5 MG Tablet for Oral Suspension
Full name
Tivicay PD 5 MG Tablet for Oral Suspension
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
63df5af3-b8ac-4e76-9830-2dbb340af922Tivicay PD 5 MG Tablet for Oral Suspension [PSN] · dolutegravir 5 MG Tablet for Oral Suspension [Tivicay] [SBD] · Tivicay PD 5 MG (as dolutegravir sodium) Tablet for Oral Suspension [SY] · Tivicay PD 5 MG Tablet for Oral Suspension [SY]431These highlights do not include all the information needed to use TIVICAY safely and effectively. See full prescribing information for TIVICAY. TIVICAY (dolutegravir) tablets, for oral use TIVICAY PD (dolutegravir) tablets for oral suspension Initial U.S. Approval: 201320251029